The EBiSC team is working hard to implement improvements in how EBiSC operates. Due to some short-term disruption, please get in touch via Contact@EBiSC.org if the cells you would like to access are currently listed as unavailable or you are ordering from outside of Europe.

PFIZi023-A

B217c8

iPSC line

Immediately available for distribution*
*Once all legal and processing details completed
We are currently making some changes to how EBiSC operates and because of this there is a short period of time where orders cannot be placed.

If you are interested in accessing these cells, please contact EBiSC directly. For more information about the current transition process see here.
Timepoint: 48hr post thaw
Magnification: x4
Timepoint: 48hr post thaw
Magnification: x10
Timepoint: Confluency
Magnification: x4
Timepoint: Confluency
Magnification: x10
A CLIP contains information about a cell line including any specific third party obligations relating to, for example, licensing obligations or the donor consent which affect the use of the cell line.

The EBiSC Access and Use Agreement must be completed along with an individual Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to download once you receive your EBiSC iPSC line.

General#

Cell Line

hPSCreg name PFIZi023-A
Alternative name(s)
B217c8
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.

Provider

Depositor Pfizer Limited - Pfizer (PFIZ)
Distributors
EBiSC

External Databases

hPSCreg PFIZi023-A
BioSamples SAMEA104236752
Cellosaurus CVCL_VE75
Wikidata Q54947278

General Information

This EBiSC line can be used for:
Yes
Research use: allowed
Clinical use: no
Commercial use: no

Donor Information#

General Donor Information

Sex female
Age of donor (at collection) 5-9

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • Bilateral Frontoparietal Polymicrogyria
  • BFPP
Genetic variants
GPR56 (target)
16q21
NM_005682.7:c.944_945dup
NP_005673.3:p.Val316fs
Heterozygous
SCV000247499.1
c.944_945dupTT: p.V316LeufsX8 in exon 8 in the GPR56 gene
GPR56 (target)
16q21
NM_001145771.3:c.1508T>C
NP_001139243.1:p.Leu503Pro
pLeu503Pro(CTC>CCC): c.1508 T>C in exon 12 in the GPR56 gene

Karyotyping (Donor)

Has the donor karyotype been analysed?
No

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA104236753

hIPSC Derivation#

General

Source cell type
A leukocyte with a single non-segmented nucleus in the mature form found in the circulatory pool of blood.
Source cell type (free text) Erythroblast
Age of donor (at collection) 5-9

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
No
Methods used
RT-PCR

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Latest released batch

Culture medium mTeSR™1
Passage method EDTA
Surface coating Matrigel / Geltrex
O2 concentration 21
CO2 concentration 5
Temperature 37
The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 20 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
SSEA-1
No
SSEA-4
Yes
TRA 1-60
Yes
POU5F1 (OCT-4)
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
FOXA2
No
GSC
Yes
PITX1
Yes
SOX17
No
GATA6
No
CXCR4
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
VIM
Yes
NCAM1
Yes
MIXL1
No
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
PAX6
Yes
NeuroD1
Yes
HES5
Yes

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Sterility

Inoculation for microbiological growth No Contaminants Detected
Mycoplasma Not Detected
Viability Viable post-cryopreservation

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
13/15 Diploid femal karyotype (46,XX), 1/15 45,XX,-4, 1/15 45,XX,-21
Karyotyping method: G-Banding

Other Genotyping (Cell Line)